Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450(a)(1). Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.